For starters, Covid hospital data is now significantly under-reported.
Since April 2023, most patients with Covid symptoms are no longer tested to confirm if they have Covid, unless they are eligible for antiviral treatment…
It’s clear that Covid hospitalisations and Covid deaths are under-reported since the change in testing protocols…
…so if you’re using these figures to calculate how many hospitalisations & deaths would be averted by vaccination, then these numbers will be under-estimated also.
2️⃣ The next issue is that the cost-effectiveness analysis ignores any deaths linked to post-infection sequelae.
As this article by @BawdenTom explains, the risk of having a heart attack or stroke increases significantly for 3 years after Covid infection.
Another study examined data from 4.6m adults in England and found that incidence of heart attacks & strokes was LOWER after Covid vaccination compared to those who had not been vaxxed.
This benefit is not included in the cost-effectiveness analysis.
3️⃣ The BIGGEST risk for younger people is long-term chronic illness.
The latest data from the GP-Patient Survey (July 2024) shows that 4.6% of the population now have LONG COVID.
That equates to 3.1 MILLION people across the UK!
According to the latest ONS Covid Infection Survey (March 2024), 29% of those currently suffering from Long Covid reported that their symptoms started within the last 12 months.
In other words, nearly A THIRD of people suffering from Long Covid are NEW cases since March 2023.
We also know that incidence of Long Covid is far higher in the middle age groups, particularly 45 to 64 year olds.
Another recent study revealed that the risk of developing Long Covid is DOUBLED for those who have NOT been vaccinated compared to those who have been vaccinated.
4️⃣ But it’s not just chronic illness that’s a problem.
Short-term illness (not severe enough to require hospital) is another important consideration since this can cause significant disruption to workplaces.
Covid is not seasonal. It comes in repeated waves throughout the year.
This article from @andrewgregory reveals how the cost of workplace illness has risen by 41% to £103 BILLION in 2023 (up from £73bn in 2018), according to the IPPR.
This was largely due to a loss of productivity amid “staggering” levels of presenteeism.
As a result of this flawed cost-effectiveness analysis (which excluded many of the primary benefits of vaccination), the numbers are VASTLY under-estimated.
This is why the vaccine eligibility has been so tightly restricted to only those aged 75 and over (or immunocompromised).
The really interesting thing is that ANOTHER vaccine cost-effectiveness analysis has recently been performed which DID look at some of these additional factors for the UK.
This study was recently published in the Journal of Medical Economics.
Unsurprisingly, this alternative analysis which INCLUDED benefits for averting Long Covid reached a VERY different conclusion:
Expanding vaccine eligibility to all over 50s increases the total cost of vaccination, but REMAINS cost-effective with an ICER of £10,061/QALY gained.
Some of my followers may recall that I conducted a detailed forensic analysis of the Covid vaccine ‘bespoke non-standard cost-effectiveness assessment’ methodology when it was first published just over a year ago.
You can have a read of my analysis in the thread below ⬇️
Finally, I wanted to show a side-by-side analysis of Covid vaccine eligibility in Autumn 2022 vs Autumn 2025…
It seems crazy that even those who are clinically vulnerable will no longer be eligible for protection from a Covid booster, unless they are immunosuppressed.
Here’s a comparison of the vaccine eligibility for Covid vs Flu.
The criteria is vastly different!
Too many differences to list them all, but children, clinically vulnerable people & healthcare workers are all eligible for the flu jab - but won’t be able to get a Covid booster.
So what can you do about this?
I would recommend writing to your local MP and ask them to raise concerns with the Minister for Public Health & Prevention who is responsible for vaccine policy (@GwynneMP).
Below is an excellent letter example written by @GillianSmith16 ⬇️
MHRA have finally approved the updated Novavax (JN.1) formulation for use in the UK…
…HOWEVER…
…Novavax have confirmed that this vaccine will *NOT* be available in the private market for purchase or distribution for the autumn 2024 OR spring 2025 season in Great Britain.
To help educate yourself for future articles, and to allow you to correct the erroneous content on your current article, please read the publication at the link below which gives a comprehensive breakdown of the limitations of the Cochrane Review.
If you have lots of highly-infectious Covid patients in hospital and lots of unmasked healthcare workers on poorly-ventilated wards, then of course lots of them will end up catching Covid.
Sadly, to those of us paying attention, it was no surprise at all.
No one talks about Covid anymore...
…but meanwhile, MILLIONS of people are suffering, many bedridden behind closed doors.
The GP-Patient Survey recently revealed that 4.6% of the population have Long Covid.
🚨4.6% of the population suffering from Long Covid.
That’s equivalent to 3.1 MILLION people across the UK!
And a further 9.4% said they weren’t sure. (Perhaps because they never tested at the time of their initial Covid infection so are struggling to get a formal diagnosis).